Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia TranscriptSeeking Alpha • 10/25/25
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaGlobeNewsWire • 10/24/25
Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaGlobeNewsWire • 09/19/25
Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRCSeeking Alpha • 09/10/25
Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/02/25
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to TradeZacks Investment Research • 09/01/25
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?Zacks Investment Research • 08/14/25
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/04/25
Syndax Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should KnowZacks Investment Research • 07/29/25
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025GlobeNewsWire • 07/28/25
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug ApprovalsSeeking Alpha • 07/08/25
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid LeukemiaGlobeNewsWire • 06/24/25
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025GlobeNewsWire • 06/12/25
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025GlobeNewsWire • 06/12/25